Hypertension
Conditions
Interventions
Aggressive antihypertensive therapy is to be administered by using a combination drug of an ARB and a low-dose thiazide diuretic.
Sponsors
Saga hypertension treatment study group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with essential hypertension, who have been previously treated with an ARB alone or an ARB and a calcium channel blocker for more than 1 months, however, the target blood pressure defined by the guideline for treatment of hypertension has not been achieved 2) Patients aged 20 years and older 3) Patients who fully understand the study procedures and have given written informed consent on use of their data for the study
Exclusion criteria
Exclusion criteria: 1) Patients with secondary hypertension 2) Patients with cardiac failure (NYHA grade III or IV) 3) Pregnant patients, including one trying to conceive pregnancy during the planned study period 4) Patients with severe liver dysfunction 5) Patients with renal failure (serum creatinine ≥2.0 mg/dL) 6) Patients with a history of hypersensitivity to ingredients of losartan or HCTZ 7) Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 8) Patients who are considered not eligible for the study by the attending doctor due to medical reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in office systolic blood pressure at 3 months after study initiation. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Change in office systolic blood pressure (excluding change at 3 months after study initiation), office diastolic blood pressure, home systolic blood pressure, and home diastolic blood pressure at 1, 2, 3, 6, 9 and 12 months after study initiation, and % of patients who achieved the target blood pressure - Change and % change in EQ-5D and scores in the hypertension questionnaire at 3 and 12 months after study initiation - Change and % change in blood glucose levels, serum potassium, serum uric acid, serum creatinine, serum cystatin-C, BNP and RLP-C at 3 and 12 months after study initiation | — |
Countries
Japan
Contacts
Public ContactHiroaki Kawano
Saga hypertension treatment study group secretariat
Outcome results
None listed